Gradual Titration of Semaglutide Results in Better Treatment Adherence and Fewer Adverse Events: A Randomized Controlled Open-Label Pilot Study Examining a 16-Week Flexible Titration Regimen Versus Label-Recommended 8-Week Semaglutide Titration Regimen.
Level 2 - randomized trial
Randomized controlled trial
PubMed 40673973 · doi:10.2337/dc25-0690
What was done
A 26-week randomized controlled open-label pilot study evaluated 104 patients with type 2 diabetes receiving semaglutide. Participants were assigned to either a label-recommended titration regimen (0.25 mg, 0.5 mg, and 1 mg escalated at 4-week intervals) or a flexible titration regimen (starting at 0.0675 mg using five clicks of the dose selector dial, increasing weekly by 0.0675 mg, with titration delays permitted for gastrointestinal adverse events).
What was found
Final doses were similar between groups. Only 2% of patients in the flexible titration arm withdrew due to gastrointestinal adverse events compared with 19% in the label arm (P = 0.005). The flexible arm had fewer days experiencing nausea (2.88 vs. 6.3 days; P = 0.017), less asthenia (9.8% vs. 24.5%; P = 0.047), and lower nausea incidence (45.1% vs. 64.2%; P = 0.051). Changes in HbA1c and BMI were similar between groups, though specific numbers were not reported in the abstract.
Why it matters
Gastrointestinal intolerance is a primary cause of GLP-1 receptor agonist discontinuation. A gradual, symptom-responsive titration schedule can substantially improve treatment adherence and tolerability without compromising glycemic or weight-loss efficacy.
Limits
Small sample size (n = 104) and open-label design that may introduce reporting bias for subjective symptoms. The abstract does not provide exact numerical changes or confidence intervals for HbA1c and BMI, and click-counting regimens may introduce administration error in routine clinical practice.
Cited by
- supports The standard starting dose of Ozempic (semaglutide) is 0.25 mg, escalating to 0.5 mg.